

Title (en)

TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS

Title (de)

BEHANDLUNG VON KREBS MIT ERHÖHTEN DOSEN LÖSLICHER FGFR1-FUSIONSPROTEINE

Title (fr)

TRAITEMENT DU CANCER PAR DOSAGES ÉLEVÉS DE PROTÉINES HYBRIDES DE FGFR1 SOLUBLES

Publication

**EP 2640406 A1 20130925 (EN)**

Application

**EP 11790705 A 20111114**

Priority

- US 41394010 P 20101115
- US 42146210 P 20101209
- US 2011060661 W 20111114

Abstract (en)

[origin: WO2012068030A1] The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

IPC 8 full level

**A61K 38/17** (2006.01); **A61P 35/00** (2006.01)

CPC (source: CN EP KR US)

**A61K 31/337** (2013.01 - KR); **A61K 38/179** (2013.01 - CN EP KR US); **A61K 45/06** (2013.01 - CN EP KR US); **A61P 11/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP KR); **A61P 35/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/71** (2013.01 - CN EP KR); **A61K 31/282** (2013.01 - CN); **A61K 31/337** (2013.01 - CN); **A61K 31/365** (2013.01 - CN); **A61K 31/4745** (2013.01 - CN); **A61K 31/475** (2013.01 - CN); **A61K 31/513** (2013.01 - CN); **A61K 31/519** (2013.01 - CN); **A61K 31/555** (2013.01 - CN); **A61K 31/704** (2013.01 - CN); **A61K 31/7048** (2013.01 - CN); **A61K 33/24** (2013.01 - CN); **A61K 38/38** (2013.01 - CN); **A61K 39/3955** (2013.01 - CN); **A61K 2300/00** (2013.01 - KR); **C07K 2319/00** (2013.01 - EP); **C07K 2319/30** (2013.01 - EP US)

C-Set (source: CN EP)

CN

1. **A61K 38/179 + A61K 2300/00**
2. **A61K 31/519 + A61K 2300/00**
3. **A61K 31/555 + A61K 2300/00**
4. **A61K 31/704 + A61K 2300/00**
5. **A61K 31/7048 + A61K 2300/00**
6. **A61K 33/24 + A61K 2300/00**
7. **A61K 38/38 + A61K 2300/00**
8. **A61K 39/3955 + A61K 2300/00**
9. **A61K 31/282 + A61K 2300/00**
10. **A61K 31/337 + A61K 2300/00**
11. **A61K 31/365 + A61K 2300/00**
12. **A61K 31/4745 + A61K 2300/00**
13. **A61K 31/475 + A61K 2300/00**
14. **A61K 31/513 + A61K 2300/00**

EP

**A61K 38/179 + A61K 2300/00**

Citation (search report)

See references of WO 2012068030A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2012068030 A1 20120524**; AU 2011329125 A1 20130502; AU 2011329125 B2 20150730; AU 2011329127 A1 20130502; AU 2011329127 B2 20150903; BR 112013012040 A2 20160816; BR 112013012041 A2 20161108; CA 2817537 A1 20120524; CA 2817583 A1 20120524; CN 103347514 A 20131009; CN 103347514 B 20170208; CN 107050426 A 20170818; EA 025828 B1 20170228; EA 201390716 A1 20140228; EA 201390722 A1 20131129; EP 2640377 A1 20130925; EP 2640377 B1 20181226; EP 2640406 A1 20130925; IL 226248 A0 20130731; IL 226252 A0 20130731; IL 226252 B 20180531; JP 2013543870 A 20131209; JP 2014500873 A 20140116; JP 2016196475 A 20161124; JP 2017019843 A 20170126; JP 5945277 B2 20160705; JP 6178240 B2 20170809; KR 101910779 B1 20181022; KR 20130114676 A 20131018; KR 20130124513 A 20131114; KR 20180053420 A 20180521; MX 2013005387 A 20131017; MX 2013005388 A 20131104; MX 349293 B 20170721; NZ 610487 A 20150327; NZ 610538 A 20150227; NZ 703786 A 20160826; NZ 703919 A 20160429; SG 190248 A1 20130628; SG 190788 A1 20130731; WO 2012068032 A1 20120524; ZA 201303501 B 20160727; ZA 201303573 B 20160727

DOCDB simple family (application)

**US 2011060661 W 20111114**; AU 2011329125 A 20111114; AU 2011329127 A 20111114; BR 112013012040 A 20111114; BR 112013012041 A 20111114; CA 2817537 A 20111114; CA 2817583 A 20111114; CN 201180064851 A 20111114; CN 201710017991 A 20111114; EA 201390716 A 20111114; EA 201390722 A 20111114; EP 11784918 A 20111114; EP 11790705 A 20111114; IL 22624813 A 20130509; IL 22625213 A 20130509; JP 2013538984 A 20111114; JP 2013538985 A 20111114; JP 2016106022 A 20160527; JP 2016175357 A 20160908; KR 20137015394 A 20111114; KR 20137015424 A 20111114; KR 20187012882 A 20111114;

MX 2013005387 A 201111114; MX 2013005388 A 201111114; NZ 61048711 A 201111114; NZ 61053811 A 201111114; NZ 70378611 A 201111114;  
NZ 70391911 A 201111114; SG 2013036348 A 201111114; SG 2013036355 A 201111114; US 2011060666 W 201111114;  
ZA 201303501 A 20130514; ZA 201303573 A 20130516